Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplenex in glaucoma
RBR-95qrz8gPhase 4Completed
- Sponsor
- Federal University of São Paulo
- Start
- Mar 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bimatoprost + brimonidine + timolol, bimatoprost, timolol and brimonidine in open-angle glaucoma (OAG) and primary angle-closure glaucoma (PACG), sponsored by Federal University of São Paulo. Started Mar 2021; status: completed.
02
Drugs
bimatoprost + brimonidine + timololbimatoprosttimololbrimonidine
03
Conditions
open-angle glaucoma (OAG)primary angle-closure glaucoma (PACG)
Beyond the preview
Go deeper on RBR-95qrz8g.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-95qrz8g.